Empagliflozin for Management of T2D in High Cardiovascular Risk Patients

MedSynapse, Connecting doctors globally. Community of Doctors This article discusses the EMPA-REG OUTCOME study that looked at the impact of empagliflozin versus placebo on CV morbidity and mortality in T2DM patients receiving standard therapy and at high risk for CV events  Dr. Aeni Bahri 🕐 3 Mins Read Learn More about Empagliflozin Efficacy This email is intended for Dr. Renukaprasad A R Unsubscribe / Change your email preferences. © 2023 MedSynapse, USA, Singapore, India, Dubai